You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The latest news on next-generation sequencing.
The increase in total revenues was driven primarily by sales of Natera's Panorama and Horizon reproductive health tests.
The firm will use the funding to expand access to its microbial cell-free DNA technology to help doctors diagnose infectious disease.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
PacBio will try to take the Sequel II to the clinic in China with the help of Berry Genomics and is open to partnerships globally, including with Illumina.
Paired tumor/germline analysis is not routinely done in cancer care, but some labs are starting to report incidental germline findings alongside patient's tumor profiles.
The University of Utah spinout said it will use the funding to enhance and expand its NGS-based Explify microbe identification platform and support its lab.
The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.
The firm presented the results of an internal validation study earlier this month at a conference, which applied the amplicon-based tool in hematological cancers.
The Seattle-based immune sequencing firm will not receive any proceeds from the sale of the shares.